Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

55
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
55
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

654
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
654
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

49
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
49
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

299
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
299
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

984
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
984
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.4K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Syndemic interactions in northwest Italy: education, place of birth, and the co-occurrence of type 2 diabetes and depression.

Social science & medicine (1982)·2026
Same author

Association between socioeconomic position and transitions to multimorbidity involving major chronic diseases in Northwest Italy.

npj aging·2026
Same author

Risk of myocardial infarction and stroke after breast cancer: an analysis of a population of 1.3 million women from North-West Italy.

Breast cancer research and treatment·2026
Same author

Embedding equity and diversity principles in a complex multinational setting: methods, tools, capacity development and experiences from the first year of the Joint Action on Cardiovascular Diseases and Diabetes (JACARDI).

BMJ global health·2025
Same author

Risk of Cardiovascular and Cerebrovascular Diseases in Patients with Myeloid Neoplasms: Results from 1.8 Million Inhabitants of Northwest Italy.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025
Same author

Hypertension, Diabetes and Depression as Modifiable Risk Factors for Dementia: A Common Data Model Approach in a Population-Based Cohort, with Study Protocol and Preliminary Results.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Mar 2, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.9K

[Community pharmacy; towards a new model.]

Teresa Spadea1, Paola Brusa2, Roberto Gnavi1

  • 1Servizio Sovrazonale di Epidemiologia, ASL TO3 Regione Piemonte.

Recenti Progressi in Medicina
|May 12, 2017
PubMed
Summary
This summary is machine-generated.

Community pharmacies in Italy are emerging as key health hubs for chronic disease prevention, especially for diabetes. This model shows promise in early detection and improving care, particularly for disadvantaged populations.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
14:32

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

24.9K

Related Experiment Videos

Last Updated: Mar 2, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.9K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
14:32

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care

Published on: February 16, 2011

24.9K

Area of Science:

  • Public Health
  • Pharmaceutical Care
  • Health Services Research

Background:

  • The evolving role of community pharmacies in healthcare systems.
  • The increasing prevalence of chronic diseases like diabetes.
  • The need for accessible and equitable health interventions.

Purpose of the Study:

  • To evaluate a community pharmacy model for diabetes prevention in Piedmont, Italy.
  • To assess the early detection of undiagnosed diabetes and high-risk individuals.
  • To provide counseling for non-adherent diabetic patients.

Main Methods:

  • Implementation and evaluation of a community pharmacy-based intervention.
  • Focus on early detection of diabetes and risk assessment.
  • Counseling for patients with suboptimal therapeutic adherence.

Main Results:

  • Community pharmacies can effectively implement preventive actions for diabetes.
  • The model shows particular effectiveness among socio-economically disadvantaged groups.
  • Potential to reduce health inequalities in diabetes care.

Conclusions:

  • The community pharmacy model offers a viable strategy for diabetes prevention.
  • This approach can help mitigate health disparities.
  • Further cost-effectiveness analysis using health information systems is warranted.